Unknown

Dataset Information

0

A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer.


ABSTRACT:

Purpose

GC1118 is a novel antibody targeting epidermal growth factor receptor (EGFR) with enhanced blocking activity against both low- and high-affinity EGFR ligands. A phase 1b/2a study was conducted to determine a recommended phase 2 dose (RP2D) of GC1118 in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) (phase 1b) and to assess the safety and efficacy of GC1118 plus FOLFIRI as a second-line therapy for recurrent/metastatic colorectal cancer (CRC) (phase 2a).

Materials and methods

Phase 1b was designed as a standard 3+3 dose-escalation study with a starting dose of GC1118 (3 mg/kg/week) in combination with biweekly FOLFIRI (irinotecan 180 mg/m2; leucovorin 400 mg/m2; 5-fluorouracil 400 mg/m2 bolus and 2,400 mg/m2 infusion over 46 hours) in patients with solid tumors refractory to standard treatments. The subsequent phase 2a part was conducted with objective response rate (ORR) as a primary endpoint. Patients with KRAS/NRAS/BRAF wild-type, EGFR-positive, recurrent/metastatic CRC resistant to the first-line treatment were enrolled in the phase 2a study.

Results

RP2D of GC1118 was determined to be 3 mg/kg/wk in the phase 1b study (n=7). Common adverse drug reactions (ADRs) observed in the phase 2a study (n=24) were acneiform rash (95.8%), dry skin (66.7%), paronychia (58.3%), and stomatitis (50.0%). The most common ADR of ≥ grade 3 was neutropenia (33.3%). ORR was 42.5% (95% confidence interval [CI], 23.5 to 62.0), and median progression-free survival was 6.7 months (95% CI, 4.0-8.0).

Conclusion

GC1118 administered weekly at 3 mg/kg in combination with FOLFIRI appears as an effective and safe treatment option in recurrent/metastatic CRC.

SUBMITTER: Lee KW 

PROVIDER: S-EPMC11016642 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer.

Lee Keun-Wook KW   Han Sae-Won SW   Kim Tae Won TW   Ahn Joong Bae JB   Baek Ji Yeon JY   Cho Sang Hee SH   Lee Howard H   Kim Jin Won JW   Kim Ji-Won JW   Kim Tae-You TY   Hong Yong Sang YS   Beom Seung-Hoon SH   Cha Yongjun Y   Choi Yoonjung Y   Kim Seonhui S   Bang Yung-Jue YJ  

Cancer research and treatment 20231207 2


<h4>Purpose</h4>GC1118 is a novel antibody targeting epidermal growth factor receptor (EGFR) with enhanced blocking activity against both low- and high-affinity EGFR ligands. A phase 1b/2a study was conducted to determine a recommended phase 2 dose (RP2D) of GC1118 in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) (phase 1b) and to assess the safety and efficacy of GC1118 plus FOLFIRI as a second-line therapy for recurrent/metastatic colorectal cancer (CRC) (phase 2a).<h4>  ...[more]

Similar Datasets

| S-EPMC7739009 | biostudies-literature
| S-EPMC7139359 | biostudies-literature
| S-EPMC2409570 | biostudies-other
| S-EPMC6240505 | biostudies-literature
| S-EPMC4831286 | biostudies-literature
| S-EPMC7983461 | biostudies-literature
| S-EPMC9426812 | biostudies-literature
| S-EPMC6721419 | biostudies-literature
| S-EPMC2698019 | biostudies-literature
| S-EPMC8771434 | biostudies-literature